Evidence map›Paper›PMID 31437542›Full record

ArticleJournal of the American Academy of Dermatology2020

Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma.

Connor J Maly, Helen J L Cumsky, Collin M Costello, Jessica E Schmidt, Richard J Butterfield, Nan Zhang, David J DiCaudo, Steven A Nelson, Maxwell L Smith, Shari A Ochoa and 5 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Inhibitory activity of medicinal mushroomPrecision clinical medicine · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Connor J MalyDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Helen J L CumskyDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Collin M CostelloDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Jessica E SchmidtDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Richard J ButterfieldDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
Nan ZhangDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
David J DiCaudoDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Steven A NelsonDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Maxwell L SmithDepartment of Pathology, Mayo Clinic, Scottsdale, Arizona.
Shari A OchoaDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Christian L BaumDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Thomas H NagelDepartment of Otolaryngology, Mayo Clinic, Scottsdale, Arizona.
Mark R PittelkowDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Aleksandar SekulicDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Aaron R MangoldDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona. Electronic address: mangold.aaron@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell CarcinomaR01CA179157 · NCI · MAYO CLINIC ARIZONA · PI SEKULIC, ALEKSANDAR NONE · 2014 to 2018
$1.8M
NCI NIH HHS R01 CA179157
6 · The paper itself

Abstract

backgroundInositol polyphosphate-5-phosphatase (INPP5A) has been shown to play a role in the progression of actinic keratosis to cutaneous squamous cell carcinoma (cSCC) and the progression of localized disease to metastatic disease. Currently, no cSCC biomarkers are able to risk stratify recurrent and metastatic disease.

objectiveTo determine the prognostic value of INPP5A expression in cSCC recurrent and metastatic disease.

methodsWe conducted a multicenter, single-institutional, retrospective cohort study within the Mayo Clinic Health System on the use of immunohistochemical staining to examine cSCC INPP5A protein expression in primary tumors and recurrent and metastatic disease. Dermatologists and dermatopathologists were blinded to outcome.

resultsLow staining expression of INPP5A in recurrent and metastatic disease tumors was associated with poor overall survival (OS) (31.0 months for low versus 62.0 months for high expression; P = .0272). A composite risk score (calculated as score of primary tumor + score of recurrent or metastatic disease tumor, with tumors with high expression scoring a zero and low expression a 1, score range 0-2) of 0 was predictive of improved OS compared with a composite risk score of ≥1 (hazard ratio 0.42, 95% confidence interval 0.21-0.84; P = .0113). LIMITATIONS: This is a multicenter but single institution study of a white population.

conclusionLoss of INPP5A expression predicts poor OS in recurrent and metastatic disease of cSCC.

Indexed as

AgedBiomarkersCarcinoma, Squamous CellDisease ProgressionFemaleGene ExpressionHumansImmunohistochemistryInositol Polyphosphate 5-PhosphatasesMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSkin NeoplasmsBiomarkersInositol Polyphosphate 5-PhosphatasesINPP5A protein, humanIHCimmunohistochemistryinositol polyphosphate-5-phosphataseINPP5ASCCsquamous cell carcinoma

Identifiers

PMID31437542
PMCPMC7043906
OpenAlexW2969832874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.